Institutional investors purchased a net $14.0 million shares of IMGN during the quarter ended December 2017. This may signal that the smart money is gaining interest in this company as the 80.45% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
BLACKROCK FUND ADVISORS Bought 2.9 Million shares of ImmunoGen Inc
REDMILE GROUP LLC Bought 2.8 Million shares of ImmunoGen Inc
THE VANGUARD GROUP, INC. Bought 2.3 Million shares of ImmunoGen Inc